Oncolytics Biotech Inc. ONCY Open Oncolytics Biotech Inc. in new tab
Oncolytics Biotech Inc. Analysis (ONCY)
Is Oncolytics Biotech Inc. a good investment? Oncolytics Biotech Inc. (ONCY) is currently trading at 0.8001 USD. Market analysts have a consensus price target of 4.11 USD. This suggests a potential upside from current levels.
Earnings Schedule: Oncolytics Biotech Inc. is expected to release its next earnings report on July 31, 2026. The market consensus estimate for Forward EPS is -0.27.
Investor FAQ
Does Oncolytics Biotech Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Oncolytics Biotech Inc.?
Oncolytics Biotech Inc. is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.
When is the next earnings date?
The next earnings date is projected to be July 31, 2026. The company currently has a trailing EPS of -0.28.
Company Profile
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of gastrointestinal (GI) tumors, metastatic colorectal cancer, anal cancer, and metastatic pancreatic cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies. Oncolytics Biotech Inc. was incorporated in 1998 and is headquartered in San Diego, California.
Dividends
Historical Split Corporate Actions
| Split Date | Split Ratio to 1 |
|---|---|
| May 25, 2018 | 0.110000 |
Explore Premium Features
Unlock detailed news and exclusive insights with our Premium subscription.
See Pricing Plans
Community Discussion